Sanoculis received CE mark for its MINT (minimally invasive nasal trabeculostomy) product. MINT, a stent-free platform, helps treat adult patients undergoing glaucoma angle surgery. The system utilizes a unique mechanical, semi-automated trephination technology. Its cutting-edge diameter of 0.14 mm creates precise openings in the pigmented trabecular meshwork.
Tel Aviv, Israel–based Sanoculis said in a news release that it designed its stent-free approach to elevate the standard of care. It could offer a less invasive, more effective treatment option for glaucoma patients.
Related: LUMA Vision nets FDA clearance for 4D imaging catheter
Sanoculis plans to roll out MINT in a selective commercial pre-launch later this year.
“MINT represents a substantial transformation in the field of minimally invasive glaucoma surgery (MIGS), with significant potential to improve patient outcomes and elevate the standard of care,” said Nir Israeli, co-founder and CEO of Sanoculis. “Clinical data from our prospective, single-arm study with a two-year follow-up indicate that MINT is both safe and effective in lowering intraocular pressure (IOP), while also reducing the need for glaucoma medications.”
A number of companies are currently competing in the MIGS market, which Sanoculis has now entered in Europe. Examples include Bausch+Lomb following its acquisition of Elios Vision, Glaukos and its iDose TR system and iStar and its MINIject.
